| Title |
Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma
|
|---|---|
| Published in |
Journal of Hepatocellular Carcinoma, May 2014
|
| DOI | 10.2147/jhc.s48958 |
| Pubmed ID | |
| Authors |
Stacey J Coleman, Richard P Grose, Hemant M Kocher |
| Abstract |
Hepatocellular cancer (HCC) is currently the third leading cause of cancer death worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited efficacy, as the standard systemic therapy for advanced HCC has paved a way for targeted molecular therapies for HCC. Fibroblast growth factor (FGF) signaling plays an important role in the developing embryo and the adult. The FGF signaling pathway is often hijacked by cancer cells, including HCC. Several alterations in FGF signaling correlate with poor outcome in HCC patients, suggesting that this family of signaling molecules plays an important role in the development of HCC. Multikinase inhibitors targeting FGF signaling are currently under investigation in clinical trials. This review discusses the current understanding of the biological and clinical implications of aberrant FGF signaling in the prognosis, diagnosis, and treatment of HCC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 24 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 28% |
| Student > Ph. D. Student | 5 | 20% |
| Student > Doctoral Student | 3 | 12% |
| Student > Master | 3 | 12% |
| Lecturer | 1 | 4% |
| Other | 5 | 20% |
| Unknown | 1 | 4% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 36% |
| Biochemistry, Genetics and Molecular Biology | 7 | 28% |
| Medicine and Dentistry | 3 | 12% |
| Nursing and Health Professions | 1 | 4% |
| Social Sciences | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 3 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2014.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Journal of Hepatocellular Carcinoma
#159
of 253 outputs
Outputs of similar age
#178,816
of 242,530 outputs
Outputs of similar age from Journal of Hepatocellular Carcinoma
#2
of 2 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 253 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,530 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.